Preclinical Studies Involving IGFBP-3 Are Impressive

Eric has posted above an Insmed press release regarding the utility of Insulin-like Growth Factor-Binding Protein-3 (IGFBP-3)in connection with Herceptin resistant breast cancer tumors. In prior preclinical studies IGFBP-3 has also shown its utility in generally restricting tumor growth and enhancing the effect of chemotherapeutic drugs and radiation treatment.

The cross-link below will take you to Insmed's summary of preclinical studies involving IGFBP-3. You will need Adobe Reader to view the preclincial study summaries which are presented in "pdf" format.